Customers’ Cuts to Development Spending and Discontinuation of Research Projects
First written in FY2021-Q1. 4 of 8 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2017: 3 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is making active approaches to university laboratories and the research and development departments of companies through Web-based meetings and customer visits.」
Approaches to research and development departments through customer visits and Web-based meetings are continuing, with no further deterioration described in the impact of customers' cuts in research and development expenditure and cancellation of projects. - FY2023-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies by using web conferences and visiting customers. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
The Company is continuing to approach customers' research and development activities and has reconfirmed its policy of expanding into multiple fields through Web-based meetings and customer visits. - FY2022MitigatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) actively approached university laboratories and the R&D departments of individual companies, primarily through web conferences, as the R&D activities of universities and customer companies recovered fully. As a result, it increased substantially year on year.」
The impact of customers' cuts in development expenditure and cancellation of projects has been partially mitigated as research and development activities at customer companies and universities have recovered and PIJ-related revenue has increased significantly year on year. - FY2022-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies, with web conferences becoming the primary means as the R&D activities of universities and customer companies recover fully. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
With the recognition that research and development activities at universities and customer companies have fully recovered, active approaches centered on Web-based meetings are continuing. - FY2022-Q2RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is making active approaches to university laboratories and the research and development departments of companies, with Web-based meetings at the center, as research and development activities at universities and customer companies have fully recovered.」
Research and development activities at universities and customer companies have fully recovered, and active approaches centered on Web-based meetings are continuing. - FY2022-Q1MitigatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is making active approaches to university laboratories and the research and development departments of companies, with Web-based meetings at the center, as research and development activities at universities and customer companies have fully recovered.」
Research and development activities at universities and customer companies are described as having fully recovered, and the impact of customers' cuts in development expenditure and cancellation of research projects described in the previous fiscal year has shifted to a description of recovery. - FY2021MitigatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is making active approaches, centered on Web-based meetings, to university laboratories and the research and development departments of companies as research and development activities at universities and customer companies get fully underway.」
Research and development activities at universities and customer companies have fully resumed, and active approaches centered on Web-based meetings are being made. The impact of customers' cuts in development expenditure and cancellation of projects described in the previous fiscal year has shifted to a description of recovery. - FY2021-Q1First statedAnnual report
「Pulse Injector® (hereinafter, PIJ) has been affected by customers' cuts in development expenditure and the cancellation of research projects, but is approaching university laboratories and the research and development departments of companies.」
The risk that customers' cuts in development expenditure and cancellation of research projects are affecting PIJ's business is described for the first time as an independent factor.